Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST).

Kito Y, Yamazaki K, Shoji H, Yamada T, Tsushima T, Mitani S, Shiraishi K, Yasui H, Hara H, Hirata K, Esaki T, Shinohara Y, Tsuzuki T, Kajiura S, Masuishi T, Izawa N, Baba E, Murata K, Akazawa N, Suzuki Y, Satake H, Boku N, Hyodo I, Yoshimura K, Kawakami H, Hironaka S, Muro K

Open source

DOI: 10.1016/j.ejca.2026.116688
Published: 2026 May 2
Container: European journal of cancer (Oxford, England : 1990)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ejca.2026.116688,
  title = {Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST).},
  author = {Kito Y and Yamazaki K and Shoji H and Yamada T and Tsushima T and Mitani S and Shiraishi K and Yasui H and Hara H and Hirata K and Esaki T and Shinohara Y and Tsuzuki T and Kajiura S and Masuishi T and Izawa N and Baba E and Murata K and Akazawa N and Suzuki Y and Satake H and Boku N and Hyodo I and Yoshimura K and Kawakami H and Hironaka S and Muro K},
  year = {2026},
  journal = {European journal of cancer (Oxford, England : 1990)},
  doi = {10.1016/j.ejca.2026.116688},
  url = {https://doi.org/10.1016/j.ejca.2026.116688}
}

RIS

TY  - JOUR
TI  - Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST).
AU  - Kito Y
AU  - Yamazaki K
AU  - Shoji H
AU  - Yamada T
AU  - Tsushima T
AU  - Mitani S
AU  - Shiraishi K
AU  - Yasui H
AU  - Hara H
AU  - Hirata K
AU  - Esaki T
AU  - Shinohara Y
AU  - Tsuzuki T
AU  - Kajiura S
AU  - Masuishi T
AU  - Izawa N
AU  - Baba E
AU  - Murata K
AU  - Akazawa N
AU  - Suzuki Y
AU  - Satake H
AU  - Boku N
AU  - Hyodo I
AU  - Yoshimura K
AU  - Kawakami H
AU  - Hironaka S
AU  - Muro K
PY  - 2026
JO  - European journal of cancer (Oxford, England : 1990)
DO  - 10.1016/j.ejca.2026.116688
UR  - https://doi.org/10.1016/j.ejca.2026.116688
ER  -

APA

Y, K., K, Y., H, S., T, Y., T, T., S, M., K, S., H, Y., H, H., K, H., T, E., Y, S., T, T., S, K., T, M., N, I., E, B., K, M., N, A., Y, S., H, S., N, B., I, H., K, Y., H, K., S, H., & K, M. (2026). Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST).. European journal of cancer (Oxford, England : 1990). https://doi.org/10.1016/j.ejca.2026.116688

Source records

pubmed · retrieved 2026-09-27T12:38:55.763Z